Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration aims to develop novel treatments for NASH/MASH by using Ribo's experience in the discovery and clinical development of siRNA therapeutics with Boehringer's commitment to improving the lives of people living with cardiovascular, renal and metabolic diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Large molecule
Partner/Sponsor/Collaborator: Boehringer Ingelheim GmbH
Deal Size: $2,000.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 03, 2024